<unk>  is a vaccine that prevents hepatitis<unk> . The first dose is recommended within 24 hours of<unk> irth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those<unk> orn premature. It is also recommended that health-care workers<unk> e vaccinated. In healthy people routine immunization results in more than 95% of people<unk> eing protected.<unk> lood testing to verify that the vaccine has worked is recommended in those at high risk. Additional doses may<unk> e needed in people with poor immune function<unk> ut are not necessary for most people. In those who have<unk> een exposed to the hepatitis<unk>  virus <unk> <unk> ut not immunized, hepatitis<unk>  immune globulin should<unk> e given in addition to the vaccine. The vaccine is given<unk> y injection into a muscle. Serious side effects from the<unk>  are very uncommon. Pain may occur at the site of injection. It is safe for use during pregnancy or while<unk> reastfeeding. It has not<unk> een linked to Guillain–Barré syndrome. The<unk> s are produced with recombinant DNA techniques. They are available<unk> oth<unk> y themselves and in combination with other vaccines. The first<unk>  was approved in the United States in 1981. A recombinant version came to market in 1986. It is on the World Health Organization's List of Essential Medicines.<unk> oth versions were developed<unk> y Maurice Hilleman and his team.
Hepatitis B vaccine
Hepatitis C vaccine
Hepatitis A vaccine
Hepatitis A and B vaccine
Polio vaccine
Typhus vaccine
Influenza vaccine
Dengue vaccine